Feasibility of a Consumer Based Accelerometer in Monitoring Outpatient Physical Activity: A Study in Patients With Cancer and Amyotrophic Lateral Sclerosis
This is a parallel group, single institution, prospective clinical study. The purpose of this study is to assess whether the Jawbone Up 24, a consumer based accelerometer, can be a feasible tool to study physical activity in cancer patients and patients with Amyotrophic Lateral Sclerosis (ALS).
Disease:Amyotrophic Lateral Sclerosis (ALS), Familial ALS, Sporadic ALS, Other
Study Type:Observational Study
Study Status:Not enrolling
Study Chair(s)/Principal Investigator(s):
Michael Harrison, MD Duke University
Clinicaltrials.gov ID (11 digit #):NCT02457715
Coordinating Center Contact InformationDuke University Medical Center
Full Study Summary:
Primary Outcome Measures:
Compliance rate of cancer and ALS patients using the device during a 14 week period. [ Time Frame: 14 weeks ] [ Designated as safety issue: No ]
Secondary Outcome Measures:
Number of steps per day in cancer patients. [ Time Frame: 14 weeks ] [ Designated as safety issue: No ]
Karnofsky performance status in cancer patients. [ Time Frame: 14 weeks ] [ Designated as safety issue: No ]
Study Sponsor:Duke University
Estimated Study Start Date:06/30/2015
Estimated Study Completion Date:06/30/2017
Posting Last Modified Date:01/11/2018
Date Study Added to alsconsortium.org:08/19/2015
Time since Symptom Onset:
Time since Diagnosis:
Can participants use Riluzole?Yes
This is a parallel group, single institution, prospective clinical study.
Patients > = 18 years of age.
Patient must be able to ambulate and complete the 6 minute walk test without use of a walker, cane, or any assist devices.
Cancer patients or ALS patients who meet the following criteria:
Histologically confirmed prostate cancer.
Patients who are initiating any hormone directed treatment for prostate cancer. Examples include GnRH agonist or antagonists (such as leuprolide, goserlin, triptorelin, histrelin and degarelix), androgen receptor blockers (such as bicalutamide or enzalutamide), or androgen biosynthesis inhibitors (such as abiraterone).
Histologically confirmed renal cell carcinoma (RCC).
Metastatic disease, in the opinion of the treating provider.
No prior systemic therapy for metastatic RCC.
Starting systemic therapy with an anti-VEGF agent (ie, sunitinib, pazopanib, etc.).
Histologically confirmed high grade glioma.
Status post concurrent radiation therapy and daily temozolomide.
Starting adjuvant temozolomide therapy.
ALS patients who are:
Already on a stable dose of Riluzole for at least one month.
Must have ALSFRS-R walking score of at least 3 or 4 and FVC at least 60% (to ensure patients are fit enough for ambulation and physical activity).
- Technology requirement:
Patients will need to own a smart phone that can interface with the Jawbone Up 24.
Patients willing to provide their own internet access for this study. This will include either a data plan or Wi-Fi access on the patient's smart phone for use of the Jawbone App. They will also need internet access (through their smart phone or home computer) for setting up a SGHIx account. Patients are welcome to use the free guest Wi-Fi access within the Duke Outpatient clinic area for the purpose of this study.
Patients will need a home computer or adaptor with USB port to charge the Jawbone Up 24.
Non-English Speaking or inability to read and understand English
Presence of cardiovascular disease that would make physical activity risky at the discretion of the provider.
Any patient who is unable to comprehend and operate the activity tracker at the discretion of the enrolling provider.
- Site Contact Information